Pharma BD Deal Intelligence
Tyco's $4.2B stock-swap acquisition of Mallinckrodt never delivered a standalone outcome: the Kozlowski-era accounting scandal engulfed Tyco before integration matured, and the 2007 Covidien breakup spun Mallinckrodt back out, which went on to file Chapter 11 twice as an independent company over opioid and Acthar Gel liabilities.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Tyco chairman characterized Mallinckrodt's imaging, respiratory and analgesic businesses as 'strong platforms for future acquisitions and licensing…
Combination would make Tyco Healthcare the second-largest medical device manufacturer worldwide and the leader in respiratory care and bulk analgesic…
FTC required divestiture of overlapping endotracheal and laryngectomy tube product lines to preserve competition; consent order cleared the merger to close.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Tyco International acquired Mallinckrodt in a stock-swap valued at ~$4.2B ($47.50/share). Mallinckrodt brought medical imaging, respiratory care, and analgesic pharmaceuticals businesses with FY1999 revenues of $2.6B. FTC settlement preserved competition in endotracheal tubes. Closed Oct 2000.
Assessment window: 10yr post-close.
$2.6B Mallinckrodt FY1999 revenue (imaging + respiratory + analgesics)
Iodinated and gadolinium contrast agents enhance vascular and tissue visualization in CT, MRI, and ultrasound. Respiratory care covers ventilation (endotracheal/tracheostomy tubes, mechanical ventilators) and pulse oximetry. Bulk and finished opioid analgesics serve acute, chronic, and post-surgical pain.
In 2000, the diagnostic contrast market was led by GE Healthcare/Amersham (Omnipaque iohexol, Visipaque iodixanol, Magnevist gadopentetate), Bracco (Isovue iopamidol, MultiHance), and Schering AG (Magnevist, Ultravist). Mallinckrodt held strong #2-#3 positions with Optiray (ioversol, x-ray/CT), OptiMARK (gadoversetamide, MRI), Optison (perflutren ultrasound), and OctreoScan (indium-111 pentetreotide for neuroendocrine tumors). In respiratory care, Nellcor (acquired by Mallinckrodt in 1997) was the global pulse oximetry leader, competing with Masimo and Datex-Ohmeda; Mallinckrodt's airway-management line (Shiley tracheostomy, endotracheal tubes) competed with Tyco's existing Sherwood Medical and Kendall lines — triggering the FTC consent requiring divestiture overlap in tracheostomy/laryngectomy tubes. In bulk opioids, Mallinckrodt was the #1 US manufacturer of methadone, oxycodone, and morphine APIs supplying generic and branded pain franchises. Combining with Tyco's existing US Surgical, Kendall, Valleylab, and Sherwood platforms made Tyco Healthcare the world's #2 medical device company, behind only Johnson & Johnson. Source: https://www.bioworld.com/articles/478362
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Tyco International Ltd. / Mallinckrodt plc (this deal) | 2000 | $4.2B | 24 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Madison Dearborn Partners / Ikaria, Inc. | 2013 | $1.6B | 85 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 2025 | $12.0B | 65 |
← Browse all deals · How we score deals
More: 2000 deals · Respiratory deals